Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis

Cancer Gene Therapy volume 27, pages 108–111 (2020)Cite this article

To the Editor:

Multiple myeloma (MM), the incurable hematological disease, is characterized by clonal B-cell proliferation in bone marrow microenvironment [1]. In recent years, the identification of molecular markers which are related to maintaining myeloma cell proliferation is required for a further investigation of myeloma molecular mechanism and predicting of myeloma recurrence and response to chemotherapy [2]. Previous evidences assign to Bcl-2 associated athanogene (BAG) 3, a co-chaperon member of the heat shock protein 70 (HSP70), is overexpressed in multiple cancers and promotes cancer cell survival [3]. The expression of BAG3 is induced at transcriptional level by proteasome inhibitors, negatively influencing their cytotoxic activity [4]. BAG3 silencing results in a significant reduction in tumor growth, which also prolonged animal survival [5]. However, few data reflect the association between the expression of BAG3 and myeloma progression. Therefore, we investigated the possibility that BAG3 also has a vital role in MM growth.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Expression of BAG3, a proliferation gene in neoplastic plasma cells, is elevated in relapsed myeloma.
Fig. 2: BAG3 interacts with the FOXM1/Rb/E2F axis in myeloma.

References

  1. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64:422–44.

    Article  Google Scholar 

  2. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96:87–95.

    Article  Google Scholar 

  3. Behl C. Breaking BAG: the Co-Chaperone BAG3 in health and disease. Trends Pharmacol Sci. 2016;37:672–88.

    Article  CAS  Google Scholar 

  4. Wang HQ, Liu HM, Zhang HY, Guan Y, Du ZX. Transcriptional upregulation of BAG3 upon proteasome inhibition. Biochem Biophys Res Commun. 2008;365:381–5.

    Article  CAS  Google Scholar 

  5. Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M, et al. IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA. 2010;107:7497–502.

    Article  CAS  Google Scholar 

  6. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735–44.

    Article  CAS  Google Scholar 

  7. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.

    Article  CAS  Google Scholar 

  8. Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res. 2014;74:4731–40.

    Article  CAS  Google Scholar 

  9. Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, et al. Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 2015;14:642–8.

    Article  CAS  Google Scholar 

  10. Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, et al. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2016;30:873–82.

    Article  CAS  Google Scholar 

  11. Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, et al. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018;8:22.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the The Affiliated Drum Tower Hospital of Nanjing University Medical School and grants from the Jiangsu Provincial Medical Innovation Team (CXTDA2017046).

Author information

Authors and Affiliations

  1. Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China

    Hua Bai & Bing Chen

Authors
  1. Hua Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hua Bai or Bing Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bai, H., Chen, B. BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis. Cancer Gene Ther 27, 108–111 (2020). https://doi.org/10.1038/s41417-019-0154-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-019-0154-2

Search

Advanced search

Quick links